Pharma news

Updated pharma, healthcare and biotech news.

Gilead to buy Forty Seven; Akrevia Therapeutics unveils new identity; FDA approved pyrimethamine

Business Consultant, Pharma Consultant, Pharma news

Gilead Sciences has announced to purchase an Immuno-oncology company Forty Seven for USD 95.50 per share, totalling up to a deal value of...

Read More

Incyte meets endpoint in second atopic dermatitis trial; NeoTX lands USD 45 M series C; Five Prime Therapeutics’ pancreatic cancer a bust

Business Consultant, Pharma Consultant, Pharma news

Incyte meets endpoint in the second pivotal atopic dermatitis clinical trial A second phase 3 trial of Incyte’s ruxolitinib cream in...

Read More

First-ever Peanut allergy treatment; Dinutuximab misses primary endpoint; Insmed’s shares Soares

Business Consultant, Pharma Consultant, Pharma news

The US FDA has given its recommendation to the Aimmune Therapeutics’ drug, Palforzia, the first-ever treatment for Peanut Allergy....

Read More

Annovis announces IPO results; Conatus merges with Histogen; Novartis discontinues its generic journey

Business Consultant, Pharma Consultant, Pharma news

A Philadelphia-based pharmaceutical, Annovis Bio, has raised USD12 million by listing its 2 million shares at USD 6 each. The company has...

Read More

Tepezza receives approval; a new way to treat Alzheimer’s

Business Consultant, Pharma Consultant, Pharma news

Horizon Therapeutics has become the first company to receive the regulatory approval of its drug Tepezza for the cure of Thyroid Eye...

Read More

Thumbs down to NKTR-181, Lilly expands its insulin armamentarium

Business Consultant, Pharma Consultant, Pharma news

The US FDA has voted down Nektar Therapeutics’ opioid painkiller NKTR-181, designed to treat lower back pain.  The FDA’s...

Read More
Close